Clinical Trial Update: Paricalcitol on Albuminuria, Inflammation and Fibrosis on Proteinuric Chronic Renal Diseases (PALIFE Study) [Phase 4]

View source ↗

Summary

A Phase 4 PALIFE trial evaluating paricalcitol for albuminuria, inflammation, and fibrosis in proteinuric chronic kidney disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• Paricalcitol (paricalcitol)

Snippet

Sponsor: Fundación Renal Iñigo Alvarez De Toledo | Conditions: Chronic Kidney Disease, Unspecified | Phase 4 | Status: TERMINATED